Lantheus Holdings, Inc.

Good morning. Welcome to the Lanthea's first quarter 2024 conference call. All lines have been placed on mute. This call is being recorded and a replay will be available in the investor section of the company's website approximately two hours after the completion of the call and will be archived for at least 30 days. I'll now turn the call over to Mark Canarney, Vice President of Investor Relations. Mark?

Thank you. Good morning and welcome to today's call. With me today are Brian Markison, our CEO, Paul Blanchfield, our President, and Bob Marshall, our CFO. We will begin the call with prepared remarks and then open the call for Q&A. This morning we issued a press release which was furnished to the Securities and Exchange Commission under Form 8K reporting our first quarter 2024 results. The release and today's slide presentation are in the investor section of our website at Lantheus.com. Any comments made during our call could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties, which are detailed in our SEC filings. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties. Discussions during this call will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is also included in the investor section of our website. It is my pleasure to now turn the call over to our CEO, Brian.

Thank you, Mark, and good morning. This marks my first earnings call as CEO of Lantheus, and I am delighted to be here to lead this incredible team. I began my career as a pharmaceutical sales rep and have more than 40 years of experience. Throughout my career, I have successfully led commercial efforts in numerous therapeutic categories, including oncology and immunology across major global markets. Having served most recently as the chair of the board and a member of the board since 2012, I have a deep understanding of Lantheus and the radiopharmaceutical industry and am committed to partnering with our exceptional leadership team to enhance the vision, strategy, and execution necessary to remain the leading radiopharmaceutical-focused company. The outstanding start to 2024 underscores this operational excellence and innovation, as we once again delivered strong performance and made strategic investments to advance and expand our pipeline. I'm particularly proud that our products were used to impact the lives of more than 1.6 million patients and their families in the quarter. As we look to the future, Lantheus will continue to be the leading radiopharmaceutical-focused company through operational excellence and sustained innovation in diagnostics and therapeutics enhanced by AI while delivering better patient outcomes and value to stakeholders. To realize this, we will maximize the value of our existing portfolio, expand our pipeline and expertise through business development at M&A, and sustain an attractive financial profile. With that, I'll now turn the call over to Paul to speak about our existing commercial portfolio. I'll then come back and discuss our pipeline.